Skip to main content

Table 3 Multivariate linear regression analysis for predictors of length of treatment delay among 81,081 adult patients with pulmonary tuberculosis

From: Treatment delay and fatal outcomes of pulmonary tuberculosis in advanced age: a retrospective nationwide cohort study

  

Fulfilling two specific events

Fulfilling three specific events

Number

Delay (day)a

Coefficient

P-value

Delay (day)a

Coefficient

P-value

Age (years)

 20–34

9595

14 (1–71)

Reference group

 

4 (0–22)

Reference group

 

 35–49

13,319

17 (1–77)

2.11 (0.60, 3.62)

0.006

5 (0–30)

2.61 (1.35, 3.86)

<0.001

 50–64

17,347

30 (3–95)

8.13 (6.57, 9.61)

<0.001

8 (0–49)

8.61 (7.38, 9.83)

<0.001

 65–79

26,897

53 (8–122)

20.0 (18.6, 21.4)

<0.001

20 (0–71)

17.7 (16.6, 18.9)

<0.001

 80 and above

13,923

61 (12–128)

23.2 (21.6, 24.7)

<0.001

30 (1–83)

22.7 (21.4, 24.0)

<0.001

Sex

 Female

24,914

42 (7–110)

Reference group

 

12 (0–56)

Reference group

 

 Male

56,167

35 (3–105)

−6.81 (−7.68, −5.95)

<0.001

11 (0–58)

−2.50 (−3.21, −1.78)

<0.001

Diabetes mellitus

 No

58,079

35 (4–103)

Reference group

 

10 (0–54)

Reference group

 

 Yes

23,002

46 (5–118)

2.97 (2.07, 3.87)

<0.001

14 (0–66)

1.39 (0.65, 2.14)

<0.001

Chronic obstructive pulmonary disease

 No

74,449

33 (3–100)

Reference group

 

10 (0–52)

Reference group

 

 Yes

6632

99 (32–154)

30.5 (29.1, 32.0)

<0.001

49 (7–115)

23.7 (22.5, 24.9)

<0.001

Malignancy

 No

74,017

33 (3–101)

Reference group

 

9 (0–53)

Reference group

 

 Yes

7064

85 (32–142)

25.7 (24.3, 27.2)

<0.001

44 (7–99)

19.6 (18.4, 20.7)

<0.001

End-stage renal disease

 No

79,172

36 (4–105)

Reference group

 

11 (0–56)

Reference group

 

 Yes

1909

92 (35–144)

26.5 (23.8, 29.1)

<0.001

45 (6–108)

22.2 (20.1, 24.4)

<0.001

Liver cirrhosis

 No

80,631

37 (4–107)

Reference group

 

11 (0–57)

Reference group

 

 Yes

450

82 (33–138)

29.5 (24.2, 34.7)

<0.001

44 (7–99)

24.1 (19.8, 28.5)

<0.001

Autoimmune disease

 No

80,262

37 (4–107)

Reference group

 

11 (0–57)

Reference group

 

 Yes

819

63 (13–133)

14.2 (10.3, 18.1)

<0.001

23 (0–80)

9.59 (6.35, 12.8)

<0.001

Acquired immunodeficiency syndrome

 No

80,632

37 (4–107)

Reference group

 

11 (0–57)

Reference group

 

 Yes

449

61 (7–132)

27.9 (22.6, 33.2)

<0.001

19 (0–76)

20.7 (16.4, 25.1)

<0.001

Organ transplantation

 No

80,957

37 (4–107)

Reference group

    

 Yes

124

83 (42–145)

15.4 (5.34, 25.5)

0.003

   

Pneumoconiosis

 No

81,015

37 (4–107)

Reference group

 

11 (0–57)

Reference group

 

 Yes

66

109 (63–158)

35.9 (22.2, 49.6)

<0.001

64 (14–118)

27.2 (16.0, 38.4)

<0.001

Low income

 No

78,213

37 (4–106)

Reference group

 

11 (0–57)

Reference group

 

 Yes

2868

51 (5–126)

10.1 (7.94, 12.2)

<0.001

14 (0–74)

7.88 (6.13, 9.64)

<0.001

Location of the initial healthcare visits

 Rural area

21,437

36 (4–103)

Reference group

 

10 (0–52)

Reference group

 

 Urban area

59,644

38 (4–109)

3.36 (2.46, 4.26)

<0.001

12 (0–60)

4.32 (3.58, 5.07)

<0.001

MTB-NAAT

 No

72,998

38 (4–107)

Reference group

 

11 (0–58)

Reference group

 

 Yes

8083

35 (5–104)

−2.20 (−3.51, −0.90)

0.001

13 (0–55)

−1.04 (−2.11, 0.04)

0.058

  1. Abbreviation: AIDS acquired immunodeficiency syndrome, COPD chronic obstructive pulmonary disease, MTB–NAAT Mycobacterium tuberculosis–nucleic acid amplification test
  2. aData are expressed as the median (1st–3rd quartiles)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us